MedTrace Logo

Teverelix Evaluated in Advanced Prostate Cancer

NCT04693507 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer

Conditions

  • Prostatic Adenoma

Interventions

DRUG

teverelix TFA 120 mg

Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24

DRUG

teverelix TFA 180 mg

Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24

Sponsors & Collaborators

  • Antev Ltd.

    lead INDUSTRY

Principal Investigators

  • Albertas Ulys, MD · National Cancer Institute, Vilnius, Lithuania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2022-12-05
Completion
2023-02-06

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693507 on ClinicalTrials.gov